A citation-based method for searching scientific literature

Christin Tse, Alexander R Shoemaker, Jessica Adickes, Mark G Anderson, Jun Chen, Sha Jin, Eric F Johnson, Kennan C Marsh, Michael J Mitten, Paul Nimmer, Lisa Roberts, Stephen K Tahir, Yu Xiao, Xiufen Yang, Haichao Zhang, Stephen Fesik, Saul H Rosenberg, Steven W Elmore. Cancer Res 2008
Times Cited: 1300

List of co-cited articles
1115 articles co-cited >1

Times Cited
  Times     Co-cited

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Jun Chen, Brian D Dayton, Hong Ding, Sari H Enschede, Wayne J Fairbrother,[...]. Nat Med 2013

An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Tilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, Robert C Armstrong, David J Augeri, Barbara A Belli, Milan Bruncko, Thomas L Deckwerth, Jurgen Dinges, Philip J Hajduk,[...]. Nature 2005

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Gemma L Kelly, Jia-Nan Gong, Donia M Moujalled,[...]. Nature 2016

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Joel D Leverson, Darren C Phillips, Michael J Mitten, Erwin R Boghaert, Dolores Diaz, Stephen K Tahir, Lisa D Belmont, Paul Nimmer, Yu Xiao, Xiaoju Max Ma,[...]. Sci Transl Med 2015

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Charles M Rudin, Christine L Hann, Edward B Garon, Moacyr Ribeiro de Oliveira, Philip D Bonomi, D Ross Camidge, Quincy Chu, Giuseppe Giaccone, Divis Khaira, Suresh S Ramalingam,[...]. Clin Cancer Res 2012

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, John P Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi-Lin Chiu,[...]. Lancet Oncol 2010

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.
Peter E Czabotar, Guillaume Lessene, Andreas Strasser, Jerry M Adams. Nat Rev Mol Cell Biol 2014

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, John F Gerecitano, Thomas J Kipps, Mary Ann Anderson, Jennifer R Brown, Lori Gressick,[...]. N Engl J Med 2016

Programmed anuclear cell death delimits platelet life span.
Kylie D Mason, Marina R Carpinelli, Jamie I Fletcher, Janelle E Collinge, Adrienne A Hilton, Sarah Ellis, Priscilla N Kelly, Paul G Ekert, Donald Metcalf, Andrew W Roberts,[...]. Cell 2007

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.
Jianhui Chang, Yingying Wang, Lijian Shao, Remi-Martin Laberge, Marco Demaria, Judith Campisi, Krishnamurthy Janakiraman, Norman E Sharpless, Sheng Ding, Wei Feng,[...]. Nat Med 2016

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Adriana E Tron, Matthew A Belmonte, Ammar Adam, Brian M Aquila, Lawrence H Boise, Elisabetta Chiarparin, Justin Cidado, Kevin J Embrey, Eric Gangl, Francis D Gibbons,[...]. Nat Commun 2018

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Mark F van Delft, Andrew H Wei, Kylie D Mason, Cassandra J Vandenberg, Lin Chen, Peter E Czabotar, Simon N Willis, Clare L Scott, Catherine L Day, Suzanne Cory,[...]. Cancer Cell 2006

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Sajid Khan, Xuan Zhang, Dongwen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand,[...]. Nat Med 2019

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Andrew W Roberts, John F Seymour, Jennifer R Brown, William G Wierda, Thomas J Kipps, Seong Lin Khaw, Dennis A Carney, Simon Z He, David C S Huang, Hao Xiong,[...]. J Clin Oncol 2012

BCL-2 family proteins: changing partners in the dance towards death.
Justin Kale, Elizabeth J Osterlund, David W Andrews. Cell Death Differ 2018

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.
Rumani Singh, Anthony Letai, Kristopher Sarosiek. Nat Rev Mol Cell Biol 2019

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Leena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, Philip Bonomi, David Gandara, Divis Khaira, Christine L Hann, Evelyn M McKeegan, Elizabeth Litvinovich, Philip M Hemken,[...]. J Clin Oncol 2011

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.
Yi Zhu, Tamara Tchkonia, Tamar Pirtskhalava, Adam C Gower, Husheng Ding, Nino Giorgadze, Allyson K Palmer, Yuji Ikeno, Gene B Hubbard, Marc Lenburg,[...]. Aging Cell 2015

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Yi Zhu, Tamara Tchkonia, Heike Fuhrmann-Stroissnigg, Haiming M Dai, Yuanyuan Y Ling, Michael B Stout, Tamar Pirtskhalava, Nino Giorgadze, Kurt O Johnson, Cory B Giles,[...]. Aging Cell 2016

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Delphine Merino, Gemma L Kelly, Guillaume Lessene, Andrew H Wei, Andrew W Roberts, Andreas Strasser. Cancer Cell 2018

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Sean Caenepeel, Sean P Brown, Brian Belmontes, Gordon Moody, Kathleen S Keegan, Danny Chui, Douglas A Whittington, Xin Huang, Leszek Poppe, Alan C Cheng,[...]. Cancer Discov 2018

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Pamela S Becker, Olga Frankfurt, Marina Konopleva, Andrew H Wei, Hagop M Kantarjian,[...]. Blood 2019

Structure-guided design of a selective BCL-X(L) inhibitor.
Guillaume Lessene, Peter E Czabotar, Brad E Sleebs, Kerry Zobel, Kym N Lowes, Jerry M Adams, Jonathan B Baell, Peter M Colman, Kurt Deshayes, Wayne J Fairbrother,[...]. Nat Chem Biol 2013

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
Marina Konopleva, Rooha Contractor, Twee Tsao, Ismael Samudio, Peter P Ruvolo, Shinichi Kitada, Xingming Deng, Dayong Zhai, Yue-Xi Shi, Thomas Sneed,[...]. Cancer Cell 2006

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Yonghan He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dongwen Lv,[...]. Nat Commun 2020

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
Reut Yosef, Noam Pilpel, Ronit Tokarsky-Amiel, Anat Biran, Yossi Ovadya, Snir Cohen, Ezra Vadai, Liat Dassa, Elisheva Shahar, Reba Condiotti,[...]. Nat Commun 2016

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
Simone M Schoenwaelder, Kate E Jarman, Elizabeth E Gardiner, My Hua, Jianlin Qiao, Michael J White, Emma C Josefsson, Imala Alwis, Akiko Ono, Abbey Willcox,[...]. Blood 2011

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.
Marco Demaria, Monique N O'Leary, Jianhui Chang, Lijian Shao, Su Liu, Fatouma Alimirah, Kristin Koenig, Catherine Le, Natalia Mitin, Allison M Deal,[...]. Cancer Discov 2017

The landscape of somatic copy-number alteration across human cancers.
Rameen Beroukhim, Craig H Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S Boehm, Jennifer Dobson, Mitsuyoshi Urashima,[...]. Nature 2010

The senescence-associated secretory phenotype: the dark side of tumor suppression.
Jean-Philippe Coppé, Pierre-Yves Desprez, Ana Krtolica, Judith Campisi. Annu Rev Pathol 2010

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Marjolein P Baar, Renata M C Brandt, Diana A Putavet, Julian D D Klein, Kasper W J Derks, Benjamin R M Bourgeois, Sarah Stryeck, Yvonne Rijksen, Hester van Willigenburg, Danny A Feijtel,[...]. Cell 2017

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.
Zhi-Fu Tao, Lisa Hasvold, Le Wang, Xilu Wang, Andrew M Petros, Chang H Park, Erwin R Boghaert, Nathaniel D Catron, Jun Chen, Peter M Colman,[...]. ACS Med Chem Lett 2014

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.
Jean-Philippe Coppé, Christopher K Patil, Francis Rodier, Yu Sun, Denise P Muñoz, Joshua Goldstein, Peter S Nelson, Pierre-Yves Desprez, Judith Campisi. PLoS Biol 2008

An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA.
Marco Demaria, Naoko Ohtani, Sameh A Youssef, Francis Rodier, Wendy Toussaint, James R Mitchell, Remi-Martin Laberge, Jan Vijg, Harry Van Steeg, Martijn E T Dollé,[...]. Dev Cell 2014

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
J D Leverson, H Zhang, J Chen, S K Tahir, D C Phillips, J Xue, P Nimmer, S Jin, M Smith, Y Xiao,[...]. Cell Death Dis 2015

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.
Xi Wang, Madhavi Bathina, John Lynch, Brian Koss, Christopher Calabrese, Sharon Frase, John D Schuetz, Jerold E Rehg, Joseph T Opferman. Genes Dev 2013

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.
Patrick Casara, James Davidson, Audrey Claperon, Gaëtane Le Toumelin-Braizat, Meike Vogler, Alain Bruno, Maïa Chanrion, Gaëlle Lysiak-Auvity, Thierry Le Diguarher, Jérôme-Benoît Starck,[...]. Oncotarget 2018

The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Jerry M Adams, Suzanne Cory. Cell Death Differ 2018

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure.
Robert L Thomas, David J Roberts, Dieter A Kubli, Youngil Lee, Melissa N Quinsay, Jarvis B Owens, Kimberlee M Fischer, Mark A Sussman, Shigeki Miyamoto, Åsa B Gustafsson. Genes Dev 2013

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
LaTonya J Hickson, Larissa G P Langhi Prata, Shane A Bobart, Tamara K Evans, Nino Giorgadze, Shahrukh K Hashmi, Sandra M Herrmann, Michael D Jensen, Qingyi Jia, Kyra L Jordan,[...]. EBioMedicine 2019

Senolytics and senostatics as adjuvant tumour therapy.
Susan Short, Edward Fielder, Satomi Miwa, Thomas von Zglinicki. EBioMedicine 2019

Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.
Darren J Baker, Tobias Wijshake, Tamar Tchkonia, Nathan K LeBrasseur, Bennett G Childs, Bart van de Sluis, James L Kirkland, Jan M van Deursen. Nature 2011

The BCL-2 protein family, BH3-mimetics and cancer therapy.
A R D Delbridge, A Strasser. Cell Death Differ 2015

Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL -BAX interaction.
Tareq Saleh, Valerie J Carpenter, Liliya Tyutyunyk-Massey, Graeme Murray, Joel D Leverson, Andrew J Souers, Moureq R Alotaibi, Anthony C Faber, Jason Reed, Hisashi Harada,[...]. Mol Oncol 2020

Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Andrew H Wei, Andrew W Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi,[...]. Blood Rev 2020

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Thanh-Trang Vo, Jeremy Ryan, Ruben Carrasco, Donna Neuberg, Derrick J Rossi, Richard M Stone, Daniel J Deangelo, Mark G Frattini, Anthony Letai. Cell 2012

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.